- Home
- GENB vs INVA Comparison
GENB vs INVA Comparison
Compare GENB & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GENB | INVA |
|---|---|---|
| Founded | 2018 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | GENB | INVA |
|---|---|---|
| Price | $12.58 | $23.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 5 |
| Target Price | $23.20 | ★ $32.80 |
| AVG Volume (30 Days) | 315.1K | ★ 497.7K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 816.67 |
| EPS | N/A | ★ 3.30 |
| Revenue | N/A | ★ $217,217,000.00 |
| Revenue This Year | N/A | $8.95 |
| Revenue Next Year | $16.58 | $12.65 |
| P/E Ratio | ★ N/A | $6.99 |
| Revenue Growth | N/A | ★ 62.63 |
| 52 Week Low | $11.00 | $16.52 |
| 52 Week High | $14.21 | $25.15 |
Technical Indicators
Market Signals| Indicator | GENB | INVA |
|---|---|---|
| Relative Strength Index (RSI) | 51.76 | 46.50 |
| Support Level | $11.39 | $20.56 |
| Resistance Level | $13.42 | $24.45 |
| Average True Range (ATR) | 0.73 | 0.57 |
| MACD | 0.00 | -0.13 |
| Stochastic Oscillator | 57.69 | 7.33 |
Price Performance
Historical ComparisonAbout GENB Generate Biomedicines Inc. Common Stock
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
About INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.